Hwang Bridget, Ren Justin, Wang Katherine, Williams Michael L, Yan Tristan D
Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
School of Medicine, University of New South Wales, Sydney, NSW, Australia.
Ann Cardiothorac Surg. 2024 Jul 31;13(4):311-325. doi: 10.21037/acs-2023-rcabg-0191. Epub 2024 Jul 26.
Despite the well-documented safety and feasibility of robotic coronary artery bypass grafting (CABG), widespread adoption of this approach remains limited by its steep learning curve, high procedural costs and paucity of data on longer-term efficacy. This current meta-analysis aims to provide a systematic overview of the outcomes of robot-assisted CABG, with a focus on long term graft patency and freedom from major adverse cardiac and cerebrovascular events (MACCE).
A systematic literature search of three electronic databases was conducted for studies reporting outcomes of robotic-assisted CABG, and were grouped based on whether patients underwent robot-assisted minimally invasive direct coronary artery bypass (RA-MIDCAB), totally endoscopic coronary artery bypass (TECAB) or were mixed. Perioperative and mid-to-long term results from included studies were pooled using meta-analysis of proportion or means in a random effects model.
In the quantitative analysis, thirty-nine eligible studies included 6,152 patients who underwent RA-MIDCAB, 1,729 patients who underwent TECAB and 21,642 patients who underwent either form of robot-assisted CABG. A high level of heterogeneity was observed amongst baseline characteristics. Perioperative mortality and complication rates were low. Conversion rate to full sternotomy overall was less than 3.2% [95% confidence interval (CI): 2.1-5.2%, I=39%]. At a mean follow-up duration of 5.2 years, overall graft patency was 96% for both RA-MIDCAB and TECAB, and freedom from major adverse cardiac events (MACE) or MACCE was 83.2% (95% CI: 72.0-90.4%; I=90%) for RA-MIDCAB and 91.6% (95% CI: 86.6-94.9%; I=76%) for TECAB.
Robot-assisted CABG is observed to have acceptable perioperative and mid-to-long term outcomes with promising overall graft patency.
尽管机器人冠状动脉旁路移植术(CABG)的安全性和可行性已有充分记录,但其广泛应用仍受到学习曲线陡峭、手术成本高以及长期疗效数据匮乏的限制。本荟萃分析旨在系统概述机器人辅助CABG的结果,重点关注长期移植血管通畅率以及无主要不良心脑血管事件(MACCE)。
对三个电子数据库进行系统文献检索,以查找报告机器人辅助CABG结果的研究,并根据患者是否接受机器人辅助微创直接冠状动脉旁路移植术(RA-MIDCAB)、完全内镜冠状动脉旁路移植术(TECAB)或两者混合进行分组。纳入研究的围手术期和中长期结果采用随机效应模型中的比例或均值荟萃分析进行汇总。
在定量分析中,39项符合条件的研究包括6152例行RA-MIDCAB的患者、1729例行TECAB的患者以及21642例行任何一种形式机器人辅助CABG的患者。基线特征之间存在高度异质性。围手术期死亡率和并发症发生率较低。总体转为全胸骨切开术的比例低于3.2%[95%置信区间(CI):2.1-5.2%,I=39%]。平均随访5.2年时,RA-MIDCAB和TECAB的总体移植血管通畅率均为96%,RA-MIDCAB无主要不良心脏事件(MACE)或MACCE的比例为83.2%(95%CI:72.0-90.4%;I=90%),TECAB为91.6%(95%CI:86.6-94.9%;I=76%)。
观察到机器人辅助CABG具有可接受的围手术期和中长期结果,总体移植血管通畅率前景良好。